Unicycive Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a UNCY research report →
Range $22 – $22
Price Chart
About the company
Unicycive Therapeutics, Inc. is a U. S.
- CEO
- Shalabh K. Gupta
- IPO
- 2021
- Employees
- 21
- HQ
- Mountain View, CA, US
Get TickerSpark's AI analysis on UNCY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $145.51M
- P/E
- -3.26
- Fwd P/E
- 3.02
- PEG
- -0.04
- P/S
- 0.00
- P/B
- 2.75
- EV/EBITDA
- -2.95
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -88.81%
- ROIC
- -61.44%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-572,000+0.0%
- Op Income
- $-29,517,000
- Net Income
- $-26,555,000+27.7%
- EPS
- $-1.67+70.4%
- OCF Growth
- -9.6%
- FCF Growth
- -9.4%
- 52W High
- $8.74
- 52W Low
- $3.71
- 50D MA
- $5.89
- 200D MA
- $6.39
- Beta
- 1.78
- RSI (14)
- 50
- Avg Volume
- 1.54M
No earnings-call transcripts are available for UNCY yet.
- Free Float
- 90.9%
- Shares Outstanding
- 26.70M
- Float Shares
- 24.28M
of shares held by institutions
37 13F filers
Buy/sell ratio 8.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 788.59K | ▲ 129.71K |
| Cubist Systematic Strategies, LLC | 23.95K | ▲ 23.95K |
Held by 77 ETFs
Biggest fund positions in UNCY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 14, 26 | Kenkare-Mitra Sara | other | 47,941 |
| May 14, 26 | Laumas Sandeep | other | 47,941 |
| May 14, 26 | Gupta Shalabh K. | other | 762,200 |
| May 14, 26 | Kenkare-Mitra Sara | other | 42,100 |
| May 14, 26 | Kenkare-Mitra Sara | other | 84,200 |
| May 14, 26 | Jermasek Douglas | other | 169,500 |
| May 14, 26 | Gupta Pramod | other | 169,500 |
| May 14, 26 | Townsend John | other | 169,500 |
| May 14, 26 | Laumas Sandeep | other | 42,100 |
| May 14, 26 | Laumas Sandeep | other | 84,200 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our UNCY coverage
Recent articles, reports, and earnings notes.
No research on UNCY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate UNCY report →Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Aug 12
UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation
globenewswire.com · Jul 13
UNCY: Unicycive Therapeutics Investors with Losses Should Contact Block & Leviton About Securities Fraud Investigation
globenewswire.com · Jul 13
UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.
globenewswire.com · Jul 10
UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.
businesswire.com · Jul 8
Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
businesswire.com · Jul 8
Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
businesswire.com · Jul 8
Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
businesswire.com · Jul 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.